%0 Journal Article %A Louis E. Fernandes %A Caroline G. Epstein %A Alexandria M. Bobe %A Joshua S.K. Bell %A Martin C. Stumpe %A Michael E. Salazar %A Ameen A. Salahudeen %A Ruth A. Pe Benito %A Calvin McCarter %A Benjamin D. Leibowitz %A Matthew Kase %A Catherine Igartua %A Robert Huether %A Ashraf Hafez %A Nike Beaubier %A Michael D. Axelson %A Mark D. Pegram %A Sarah L. Sammons %A Joyce A. O’Shaughnessy %A Gary A. Palmer %T Real-world Evidence of Diagnostic Testing and Treatment Patterns in U.S. Breast Cancer Patients with Implications for Treatment Biomarkers from RNA-sequencing Data %D 2020 %R 10.1101/2020.08.07.20168401 %J medRxiv %P 2020.08.07.20168401 %X INTRODUCTION We performed a retrospective analysis of longitudinal real-world data (RWD) from breast cancer patients to replicate results from clinical studies and demonstrate the feasibility of generating real-world evidence. We also assessed the value of transcriptome profiling as a complementary tool for determining molecular subtypes.PATIENTS AND METHODS De-identified, longitudinal data were analyzed after abstraction from U.S. breast cancer patient records structured and stored in the Tempus database. Demographics, clinical characteristics, molecular subtype, treatment history, and survival outcomes were assessed according to strict qualitative criteria. RNA sequencing and clinical data were used to predict molecular subtypes and signaling pathway enrichment.RESULTS The clinical abstraction cohort (n=4,000) mirrored U.S. breast cancer demographics and clinical characteristics indicating feasibility for RWE generation. Among HER2+ patients, 74.2% received anti-HER2 therapy, with ~70% starting within 3 months of a positive test result. Most non-treated patients were early stage. In this RWD set, 31.7% of patients with HER2+ IHC had discordant FISH results recorded. Among patients with multiple HER2 IHC results at diagnosis, 18.6% exhibited intra-test discordance. Through development of a whole-transcriptome model to predict IHC receptor status in the molecular sequenced cohort (n=400), molecular subtypes were resolved for all patients (n=36) with equivocal HER2 statuses from abstracted test results. Receptor-related signaling pathways were differentially enriched between clinical molecular subtypes.CONCLUSION RWD in the Tempus database mirrors the overall U.S. breast cancer population. These results suggest real-time, RWD analyses are feasible in a large, highly heterogeneous database. Furthermore, molecular data may aid deficiencies and discrepancies observed from breast cancer RWD.Competing Interest StatementAll authors with the exception of Mark D. Pegram, Sarah Sammons, and Joyce O'Shaughnessy are employees of Tempus Labs. Sarah Sammons receives research funding from Eli Lilly and Astra Zeneca, and serves on advisory boards for Daiichi Sankyo, Eli Lilly, Foundation Medicine, Novartis, and Sermonix. Joyce O'Shaughnessy has received honoraria from or serves on advisory boards for AbbVie Inc., Agendia, Amgen Biotechnology, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron Therapeautics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis, Ondonate Therapeutics, Pfizer, Puma Biotechnology, Prime Oncology, Roche, Seattle Genetics, Syndax Pharmaceuticals, and Takeda. There are no other financial interests to disclose.Funding StatementAll authors with the exception of Mark D. Pegram, Sarah Sammons, and Joyce O'Shaughnessy are employees of Tempus Labs.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was submitted to the Advarra Institutional Review Board. The IRB determined the research was exempt from IRB oversight and approved a waiver of HIPAA authorization for this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRelevant data are available within the text, figures, tables, and supplementary information. %U https://www.medrxiv.org/content/medrxiv/early/2020/08/11/2020.08.07.20168401.full.pdf